CA2976258C - Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau - Google Patents
Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau Download PDFInfo
- Publication number
- CA2976258C CA2976258C CA2976258A CA2976258A CA2976258C CA 2976258 C CA2976258 C CA 2976258C CA 2976258 A CA2976258 A CA 2976258A CA 2976258 A CA2976258 A CA 2976258A CA 2976258 C CA2976258 C CA 2976258C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- stereoisomer
- tautomer
- solvate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562117888P | 2015-02-18 | 2015-02-18 | |
| US62/117,888 | 2015-02-18 | ||
| PCT/US2016/018305 WO2016134042A2 (en) | 2015-02-18 | 2016-02-17 | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2976258A1 CA2976258A1 (en) | 2016-08-25 |
| CA2976258C true CA2976258C (en) | 2024-02-20 |
Family
ID=56692299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2976258A Active CA2976258C (en) | 2015-02-18 | 2016-02-17 | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10618899B2 (enExample) |
| EP (1) | EP3259274B1 (enExample) |
| JP (1) | JP6830895B2 (enExample) |
| KR (1) | KR102220260B1 (enExample) |
| CN (1) | CN107709326B (enExample) |
| AU (1) | AU2016220049C1 (enExample) |
| CA (1) | CA2976258C (enExample) |
| WO (1) | WO2016134042A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107709326B (zh) | 2015-02-18 | 2021-12-17 | 巴克老龄问题研究所 | 降低应激诱导的p-tau的三唑并吡啶和三唑并嘧啶 |
| WO2020231723A1 (en) | 2019-05-13 | 2020-11-19 | Ecolab Usa Inc. | 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor |
| ES2932481B2 (es) * | 2021-07-09 | 2023-09-11 | Consejo Superior Investigacion | Compuestos inhibidores de la quinasa de tau y tubulina (ttbk) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2174080A1 (en) | 1993-10-12 | 1995-04-20 | Paul Edward Aldrich | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
| US6107300A (en) * | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| WO1999011643A1 (en) * | 1997-09-02 | 1999-03-11 | Du Pont Pharmaceuticals Company | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
| KR20030016222A (ko) | 2000-02-14 | 2003-02-26 | 니뽄 다바코 산교 가부시키가이샤 | 수술후 스트레스 예방ㆍ치료제 |
| WO2004037159A2 (en) | 2002-10-23 | 2004-05-06 | Obetherapy Biotechnology | Compounds, compositions and methods for modulating fat metabolism |
| WO2007076055A2 (en) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| AU2011291506B2 (en) | 2010-08-19 | 2016-07-28 | Buck Institute For Age Research | Methods of treating mild cognitive impairment (mci) and related disorders |
| AU2012290116B2 (en) | 2011-08-02 | 2016-11-03 | Buck Institute For Research On Aging | Tropinol esters and related compounds to promote normal processing of APP |
| WO2013026021A2 (en) | 2011-08-18 | 2013-02-21 | Buck Institute For Research On Aging | Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease |
| USRE49873E1 (en) | 2012-03-19 | 2024-03-19 | Buck Institute For Research On Aging | APP specific bace inhibitors (ASBIs) and uses thereof |
| US9649317B2 (en) * | 2012-09-19 | 2017-05-16 | The Trustees Of The University Of Pennsylvania | Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies |
| WO2014127042A1 (en) | 2013-02-12 | 2014-08-21 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| CN107709326B (zh) | 2015-02-18 | 2021-12-17 | 巴克老龄问题研究所 | 降低应激诱导的p-tau的三唑并吡啶和三唑并嘧啶 |
-
2016
- 2016-02-17 CN CN201680017456.6A patent/CN107709326B/zh active Active
- 2016-02-17 EP EP16752995.7A patent/EP3259274B1/en active Active
- 2016-02-17 JP JP2017543785A patent/JP6830895B2/ja active Active
- 2016-02-17 AU AU2016220049A patent/AU2016220049C1/en active Active
- 2016-02-17 KR KR1020177025850A patent/KR102220260B1/ko active Active
- 2016-02-17 CA CA2976258A patent/CA2976258C/en active Active
- 2016-02-17 WO PCT/US2016/018305 patent/WO2016134042A2/en not_active Ceased
- 2016-02-17 US US15/548,402 patent/US10618899B2/en active Active
-
2020
- 2020-02-21 US US16/797,846 patent/US10844071B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200190094A1 (en) | 2020-06-18 |
| JP6830895B2 (ja) | 2021-02-17 |
| CA2976258A1 (en) | 2016-08-25 |
| WO2016134042A2 (en) | 2016-08-25 |
| EP3259274A2 (en) | 2017-12-27 |
| AU2016220049B2 (en) | 2020-09-24 |
| US20180346466A1 (en) | 2018-12-06 |
| EP3259274B1 (en) | 2023-06-28 |
| CN107709326B (zh) | 2021-12-17 |
| KR102220260B1 (ko) | 2021-02-25 |
| CN107709326A (zh) | 2018-02-16 |
| EP3259274A4 (en) | 2018-08-01 |
| AU2016220049C1 (en) | 2021-02-25 |
| AU2016220049A1 (en) | 2017-08-24 |
| US10618899B2 (en) | 2020-04-14 |
| JP2018505899A (ja) | 2018-03-01 |
| KR20170117185A (ko) | 2017-10-20 |
| US10844071B2 (en) | 2020-11-24 |
| WO2016134042A3 (en) | 2016-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11091444B2 (en) | Hydantoins that modulate BACE-mediated app processing | |
| US10835546B2 (en) | App specific BACE inhibitors (ASBIs) and uses thereof | |
| US10844071B2 (en) | Substituted [1,2,3]triazolo[4,5-d]pyrimidines that lower stress-induced p-tau | |
| US11642352B2 (en) | Methods of treating wandering in Lewy dody dementia | |
| EP3510029B1 (en) | Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition | |
| US20220041553A1 (en) | Apoe4-targeted theraputics that increase sirt1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200226 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250203 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250203 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260209 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260209 |